Antimicrobial Resistance (AMR) is a serious and growing global public health threat. Resistant pathogens often cause opportunistic infections, thriving in hospitals and medical environments where patients are more vulnerable due to viral lung infections like flu, SARS, and COVID-19.
It is therefore crucial that effective antiviral treatments are found to tackle COVID-19, and that broader testing for rapid diagnosis and early treatment of secondary bacterial infections becomes a key part of the response.
Although more research is needed to investigate the link between COVID-19, secondary bacterial infections, and mortality rates, it is clear that Antimicrobial Susceptibility Testing (AST) will need to play a vital role in the treatment programs of patients with COVID-19. By quickly establishing the resistance profile of the bacteria, clinicians can provide the most appropriate antibiotics to fight the infection as soon as possible.
Our phenotypic Merlin MICRONAUT AST method is based on the broth microdilution approach, the worldwide reference method for determination of the minimal inhibitory concentration (MIC).
Merlin MICRONAUT offers a complete range of Specialty AST (Yeast, Fastidious, Anaerobes) and unique MIC strips designed for convenient and cost-effective testing of critical drugs. The MICRONAUT system can interface with our market leading MALDI Biotyper®, which quickly and accurately identifies thousands of microbial species, thus helping to provide clinicians with actionable information for the best possible treatment of COVID-19 patients.
Please contact your local representative for availability in your country.
Not for sale in the USA.